Jiun-Sheng Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiun-Sheng Chen has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Chad D. Huff
University of Texas MD Anderson Cancer Center
31 shared publications - Amado Zurita-Saavedra
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Ana M. Aparicio
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Andrew W. Hahn
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Christopher J. Logothetis
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Haswanth Vundavilli
Department of Electrical Engineering, IIT (ISM), Dhanbad, India
29 shared publications
Latest Publications
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S1. PSA and CTC status at module allocation, after 8 weeks of AAPA treatment.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S1. PSA and CTC status at module allocation, after 8 weeks of AAPA treatment.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S4. Immune cell densities by IHC across organ sites.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S4. Immune cell densities by IHC across organ sites.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S5. Tumor purity.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S5. Tumor purity.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S9. Whole exome sequencing (WES)-based identification of pathogenic somatic mutations.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S9. Whole exome sequencing (WES)-based identification of pathogenic somatic mutations.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S3. Immune cell populations in baseline metastatic biopsies within Satisfactory and Unsatisfactory groups.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S3. Immune cell populations in baseline metastatic biopsies within Satisfactory and Unsatisfactory groups.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S5. Tumor purity.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S5. Tumor purity.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S10. Frequencies of copy number alterations.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S10. Frequencies of copy number alterations.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Criteria and Definitions: Trial eligibility criteria, dose reductions, failure-free survival
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Criteria and Definitions: Trial eligibility criteria, dose reductions, failure-free survival
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Criteria and Definitions: Trial eligibility criteria, dose reductions, failure-free survival
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Criteria and Definitions: Trial eligibility criteria, dose reductions, failure-free survival
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Table S2. Pathogenic mutations in germline DNA.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Table S2. Pathogenic mutations in germline DNA.